Target Price | CHF101.72 |
Price | CHF98.62 |
Potential | 3.14% |
Number of Estimates | 22 |
22 Analysts have issued a price target Novartis 2026 . The average Novartis target price is CHF101.72. This is 3.14% higher than the current stock price. The highest price target is CHF122.82 24.53% , the lowest is CHF79.23 19.66% . | |
A rating was issued by 28 analysts: 5 Analysts recommend Novartis to buy, 19 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2026 of 3.14% . Most analysts recommend the Novartis stock at Hold. |
20 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF46.9b . This is 5.79% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF49.4b 11.47% , the lowest is CHF44.8b 1.17% .
This results in the following potential growth metrics:
2024 | CHF44.3b | 8.52% |
---|---|---|
2025 | CHF46.9b | 5.79% |
2026 | CHF47.7b | 1.65% |
2027 | CHF49.0b | 2.76% |
2028 | CHF50.8b | 3.65% |
2029 | CHF52.0b | 2.40% |
16 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF18.9b . This is 0.02% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF20.0b 5.84% , the lowest is CHF15.4b 18.56% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | CHF18.8b | 3.79% |
---|---|---|
2025 | CHF18.9b | 0.61% |
2026 | CHF19.3b | 2.00% |
2027 | CHF20.1b | 4.21% |
2028 | CHF20.7b | 2.88% |
2029 | CHF23.2b | 12.42% |
2024 | 42.40% | 4.36% |
---|---|---|
2025 | 40.32% | 4.90% |
2026 | 40.46% | 0.35% |
2027 | 41.04% | 1.43% |
2028 | 40.73% | 0.76% |
2029 | 44.72% | 9.80% |
13 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF11.5b . This is 11.89% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF13.4b 30.29% , the lowest is CHF9.2b 10.21% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF10.3b | 18.97% |
---|---|---|
2025 | CHF11.5b | 11.89% |
2026 | CHF12.2b | 5.85% |
2027 | CHF12.8b | 5.39% |
2028 | CHF14.1b | 10.13% |
2029 | CHF15.1b | 6.63% |
2024 | 23.22% | 25.33% |
---|---|---|
2025 | 24.56% | 5.76% |
2026 | 25.58% | 4.15% |
2027 | 26.23% | 2.54% |
2028 | 27.87% | 6.25% |
2029 | 29.02% | 4.13% |
13 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is CHF5.83 . This is 11.90% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF6.79 30.33% , the lowest is CHF4.68 10.17% .
This results in the following potential growth metrics and future valuations:
2024 | CHF5.21 | 18.97% |
---|---|---|
2025 | CHF5.83 | 11.90% |
2026 | CHF6.17 | 5.83% |
2027 | CHF6.50 | 5.35% |
2028 | CHF7.16 | 10.15% |
2029 | CHF7.64 | 6.70% |
Current | 18.92 | 40.56% |
---|---|---|
2025 | 16.92 | 10.57% |
2026 | 15.98 | 5.56% |
2027 | 15.16 | 5.13% |
2028 | 13.77 | 9.17% |
2029 | 12.91 | 6.25% |
Based on analysts' sales estimates for 2025, the Novartis stock is valued at an EV/Sales of 4.34 and an P/S ratio of 3.99 .
This results in the following potential growth metrics and future valuations:
Current | 4.59 | 14.46% |
---|---|---|
2025 | 4.34 | 5.49% |
2026 | 4.27 | 1.63% |
2027 | 4.15 | 2.68% |
2028 | 4.01 | 3.52% |
2029 | 3.91 | 2.34% |
Current | 4.22 | 11.72% |
---|---|---|
2025 | 3.99 | 5.47% |
2026 | 3.93 | 1.63% |
2027 | 3.82 | 2.68% |
2028 | 3.69 | 3.52% |
2029 | 3.60 | 2.34% |
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Hold
➜
Hold
|
Unchanged | Jan 06 2025 |
BNP PARIBAS EXANE |
Neutral
➜
Neutral
|
Unchanged | Jan 05 2025 |
DAY BY DAY |
Buy
➜
Buy
|
Unchanged | Jan 05 2025 |
GUGGENHEIM SECURITIES LLC |
Neutral
➜
Neutral
|
Unchanged | Dec 16 2024 |
TD COWEN |
Hold
➜
Hold
|
Unchanged | Dec 10 2024 |
STIFEL EUROPE |
Buy
➜
Hold
|
Downgrade | Nov 24 2024 |
HSBC |
Hold
➜
Hold
|
Unchanged | Nov 24 2024 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Jan 06 2025 |
Unchanged
BNP PARIBAS EXANE:
Neutral
➜
Neutral
|
Jan 05 2025 |
Unchanged
DAY BY DAY:
Buy
➜
Buy
|
Jan 05 2025 |
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
|
Dec 16 2024 |
Unchanged
TD COWEN:
Hold
➜
Hold
|
Dec 10 2024 |
Downgrade
STIFEL EUROPE:
Buy
➜
Hold
|
Nov 24 2024 |
Unchanged
HSBC:
Hold
➜
Hold
|
Nov 24 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.